Continuous glucose monitoring devices could overstate blood sugar levels, with a study revealing inconsistencies in readings compared with traditional methods.

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with ...

The following is a summary of “Evidence for improved glucose metrics and perinatal outcomes with continuous glucose ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM ...

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe.

Abbott's growth potential with GLP-1 tailwinds, robust FCF, and dividend growth. Read more on how ABT navigates tariffs while ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via ... Abbott has made the development of wearables a key part of its device strategy, and is drawing ...

(Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM ... lifestyle behaviour change. Based in part on UK pricing for the device, which William ...

Rapid implementation of software as a medical device (SaMD) in point-of-care (PoC) diagnostics contributed to market revenue growth. Hospitals, clinics, and healthcare professionals use SaMD to ...